Stanford University

Diego Rodriguez Nominated to Stand for Election to TrueCar's Board of Directors at May 23, 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Mechanical, Business administration, Chairperson, IDEO, Harvard Business School, Acquisition, Transport, Intuit, Stanford University, Bachelor, TrueCar, Fintech, Partnership, LendingTree, Annual general meeting, Management

Mr. Rodriguez would fill the vacancy created by Erin Lantz, who is retiring from service on the Board at the Annual Meeting.

Key Points: 
  • Mr. Rodriguez would fill the vacancy created by Erin Lantz, who is retiring from service on the Board at the Annual Meeting.
  • "On behalf of the entire board, I extend our heartfelt gratitude to Erin Lantz for eight years of dedicated service.
  • Her contributions have been invaluable, and we wish her the very best in her future endeavors," said Barbara Carbone, Board Chair.
  • He is currently a board member at LendingTree and was on the board of EngageSmart until its January 2024 acquisition.

Alliance College-Ready Public Schools' Exceptional Teacher Pay Helps Shape Exceptional Scholar Outcomes

Retrieved on: 
Monday, April 8, 2024
Learning, Achievement Medal, Secondary school, ELA, Research, Talent, Child, Alliance College-Ready Public Schools, Mentorship, Student, News, California Distinguished School, Investment, CREDO, LOS, Stanford University, Social, Counselor, Teaching, Tutoring

LOS ANGELES, April 8, 2024 /PRNewswire/ -- Studies show that teachers are the most important factor when it comes to a child's learning in school, and a caring adult – in and out of school – is critical to developing the whole child. Yet, post pandemic, school districts across the country continue to struggle with acute staff shortages due to burnout. In California, for example, 37.1% of teaching positions are currently unfilled. Understanding this, Alliance College-Ready Public Schools is currently hiring, and are offering above average pay for this all important educator role.

Key Points: 
  • Understanding this, Alliance College-Ready Public Schools is currently hiring , and are offering above average pay for this all important educator role.
  • This is an average increase of over 42% from the last new teacher scale implemented at Alliance schools in the 2020-2021 year.
  • 90% of Alliance teachers have said they plan to stay at Alliance, and 80% of staff say they would recommend Alliance to a friend.
  • Alliance schools have received prestigious recognition from the National Blue Ribbon School Awards and the California Gold Ribbon Awards.

McCann Systems Recognizes Exceptional STEM Talent with 2024 Scholarship Awards

Retrieved on: 
Monday, April 8, 2024
Villanova University, Electrical engineering, Computer science, Mechanical engineering, Essay, Blockchain, Education, Creative writing, Mississippi State University, AI, University, Computer, Student, Marketing, STEM, Stanford University, Artificial intelligence, Cryptocurrency

WALLINGFORD, Conn., April 8, 2024 /PRNewswire/ -- McCann Systems , a renowned commercial audiovisual integrator, is proud to announce the results of its highly anticipated annual STEM Scholarship competition .

Key Points: 
  • WALLINGFORD, Conn., April 8, 2024 /PRNewswire/ -- McCann Systems , a renowned commercial audiovisual integrator, is proud to announce the results of its highly anticipated annual STEM Scholarship competition .
  • This year, in recognition of the exceptional pool of applicants, McCann expanded the field to three winners, each receiving substantial awards toward their higher education.
  • Catherine added, "Nice to meet the other candidates, and thank you, McCann Systems, for sponsoring the scholarship.
  • McCann Systems remains committed to supporting and empowering the next generation of STEM leaders, and the annual STEM Scholarship reflects this continued dedication.

Paralyzed Veterans of America to Honor L'Oréal USA with PVA Disability Innovation Award at Igniting Change Gala on April 12

Retrieved on: 
Monday, April 8, 2024
Storm, Astronaut, Research, Gordon H. Mansfield, Microsoft, Penske Truck Leasing, Employment, Organization, Veteran, Woman, Yale University, Maybelline, Beauty, Target, Target Corporation, Communication, University, PVA, Paralyzed Veterans of America, Stanford University, Human, TriWest Healthcare Alliance, Marketing, NASA, Penske Automotive Group, Microsoft Teams, Disability, Sport, Government, Hand, Hospital

WASHINGTON, April 8, 2024 /PRNewswire/ -- On Friday, April 12, Paralyzed Veterans of America will host its Igniting Change Gala and present the PVA Disability Innovation Award to L'Oréal USA, the largest subsidiary of the L'Oréal Groupe, the worldwide beauty leader.

Key Points: 
  • WASHINGTON, April 8, 2024 /PRNewswire/ -- On Friday, April 12, Paralyzed Veterans of America will host its Igniting Change Gala and present the PVA Disability Innovation Award to L'Oréal USA, the largest subsidiary of the L'Oréal Groupe, the worldwide beauty leader.
  • L'Oréal USA was chosen as it has been a leader committed to driving greater inclusion in the beauty industry.
  • L'Oréal USA actively supports the veteran community through various community initiatives led by VALOR, its employee-led resource group dedicated to veterans.
  • "PVA commends L'Oréal for its important contributions to disability innovation and inclusion, as they exemplify the spirit of our organization's own history of innovation."

CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, B-cell lymphoma, Disease, Patient, SAN, G&A, Cancer, IPO, Stanford University, Trial of the century, Therapy, Safety, CD19, Pharmaceutical industry

SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023.

Key Points: 
  • CARGO had $405.7 million in cash and cash equivalents as of December 31, 2023, which it expects will fund operations through 2025.
  • Research and development (R&D) expenses were $27.1 million for the fourth quarter of 2023, which includes $0.7 million of non-cash stock-based compensation expense.
  • General and administrative (G&A) expenses were $7.9 million for the fourth quarter of 2023, which includes $1.0 million of non-cash stock-based compensation expense.
  • For 2023, net loss was $98.1 million, or $16.53 per share, including non-cash stock-based compensation and depreciation expenses of $3.3 million and $1.5 million, respectively.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.

HR Technology Conference & Exposition® Europe Announces Additional Agenda Details

Retrieved on: 
Monday, March 18, 2024
UX, HR, Organization, Conference, Noise, Corporate sustainability, Digital, Expert, Business, General partnership, PALM, Research, Transformation, Organizational culture, Olympus Corporation, Senior, RAI Amsterdam, Avalere Health, Stanford University, ETC, Workplace, Tech, Management

WEST PALM BEACH, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- The upcoming HR Technology Conference & Exposition® Europe today shared additional agenda details in the lead-up to the two-day event taking place at the RAI Amsterdam, May 2 – 3, 2024.

Key Points: 
  • WEST PALM BEACH, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- The upcoming HR Technology Conference & Exposition® Europe today shared additional agenda details in the lead-up to the two-day event taking place at the RAI Amsterdam, May 2 – 3, 2024.
  • Beyond the previously announced keynote sessions , the HR Technology Conference Europe will feature a full slate of Tech Talks, Ask the Experts and much more.
  • Rebecca McKenna, Senior Vice President, HR Portfolio at ETC, shared, “The HR Technology Conference Europe promises to be an exceptional event that looks at the issues impacting today’s HR teams from multiple vantage points.
  • Attendees will have the opportunity to hear from industry analysts, practitioners and solution providers, all focused on advancing the HR discipline and improving the very nature of work.”
    The agenda for the HR Technology Conference & Exposition® Europe is updated on a regular basis.

The Joint Commission Establishes President's Fellowship for Healthcare Quality and Safety

Retrieved on: 
Thursday, March 14, 2024
Joint, Neuroscience, Learning, Joint Commission, National Quality Forum, Patient, Education, Research, University, Doctor of Philosophy, Howard University Hospital, Stanford School, Stanford University, Health, NQF

OAKBROOK TERRACE, Illinois, March 14, 2024 (GLOBE NEWSWIRE) -- The Joint Commission has established The President’s Fellowship for Healthcare Quality and Safety, a prestigious program for a highly qualified healthcare professional to collaborate with The Joint Commission to advance healthcare outcomes globally.

Key Points: 
  • OAKBROOK TERRACE, Illinois, March 14, 2024 (GLOBE NEWSWIRE) -- The Joint Commission has established The President’s Fellowship for Healthcare Quality and Safety, a prestigious program for a highly qualified healthcare professional to collaborate with The Joint Commission to advance healthcare outcomes globally.
  • The new fellowship, which reports directly to Joint Commission enterprise President and Chief Executive Officer Jonathan B. Perlin, MD, PhD, aligns an accomplished fellow’s specific background and achievements with key Joint Commission initiatives while supporting the Fellow’s career development as an influential leader in quality and safety.
  • “Establishing The President’s Fellowship for Healthcare Quality and Safety is an exciting way to introduce fresh perspectives to The Joint Commission’s efforts to support healthcare organizations’ delivery of safe, high-quality, equitable and compassionate care,” says Dr. Perlin.
  • Applications from mid-career healthcare professionals for The Joint Commission’s 2025 President’s Fellowship for Healthcare Quality and Safety (which spans the calendar year) are currently being accepted.

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024
JAMA, Research, Health care, Health, Public, Public health, EVP, UCSF School of Medicine, Pediatric Research, Education, UC, Global Health, Emergency medicine, Society, Publication, Emergency medical services, Hospital, Children's National Hospital, Stanford University, National academy, MHA, Pediatrics, BMJ

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
University of Illinois Urbana-Champaign, Drug discovery, Schering-Plough, Patient, Genentech, Acquisition, Cancer, Laboratory, Biology, Northern Illinois University, Stanford University, Amgen, Pharmaceutical industry

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.
  • “On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board,” said Ben Zeskind, Chief Executive Officer, Immuneering Corporation.
  • From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation.
  • in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.